Advanced Filters
noise

Hormone Deficiencies Clinical Trials

A listing of Hormone Deficiencies medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

Found 86 clinical trials
S Salsala Nasim, BS

Intralesional Cyclosporine for Alopecia Areata

Alopecia areata (AA) is a chronic autoimmune disease that causes non-scarring, focal areas of hair loss. Due to its resulting disfigurement and unpredictable course, it is recognized as a serious medical condition with severe emotional and psychosocial distress, including a high prevalence of depression and anxiety.1-4 Treatment options for alopecia …

18 - 65 years of age All Phase N/A
G Giselle Singer

Regeneron AA Multicenter (Dupilumab)

This is a prospective, randomized, double blind, placebo-controlled clinical trial. The study will take place at 4 sites. This trial will enroll a total of 68 patients with moderate to severe AA (affecting more than 50% of the scalp) at the time of screening with a targeted 54 subjects completers …

18 years of age All Phase 2

Investigate the Efficacy and Safety of Farudodstat Compared With Its Placebo in Adult Alopecia Areata Participants

The main purpose of this study is to measure the efficacy of farudodstat compared to placebo at Week 12 from the treatment start, in adult participants with Alopecia Areata (AA) with 30% or greater scalp hair loss.

18 years of age All Phase 2
E Eisa Hegazy, Assist.Prof

Evaluation of Latanoprost Combined With Fractional Erbium- YAG Laser

Alopecia areata (AA) an autoimmune disorder of hair follicles results in varying degrees of scalp, facial and body hair loss. Clinically, patients' presentation varies from patchy circumscribed scalp involvement to total body and scalp hair loss affects up to 2% of the general population. The exact pathobiology of AA has …

30 - 35 years of age All Phase 1/2
A Alison Wandling, B.S. CCRC

HCW9302 (Interleukin-2 Fusion Protein) for Alopecia Areata

This is a Phase 1, open-label, multi-center, competitive enrollment, and dose-escalation study of HCW9302 in subjects with Alopecia Areata (AA)

18 - 70 years of age All Phase 1
E Erika Alba Rojas, MD

Clinical Trial on the Efficacy of Intralesional Triamcinolone Versus Candida Albicans Antigen in Treating Alopecia Areata

The efficacy of two intralesional treatment modalities for alopecia areata will be determined. Thirty patients over the age of 6 with the diagnosis of alopecia areata on the scalp, with an extension of less than 50%, will be included. A comparison will be made between the effectiveness of intralesional Triamcinolone …

6 years of age All Phase N/A

A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants in Japan With Alopecia Areata

Alopecia areata (AA) is a disease that happens when the immune system attacks hair follicles and causes hair loss. AA usually affects the head and face, but hair loss can happen on any part of the body. The purpose of this study is to assess how safe, effective, and tolerable …

12 - 63 years of age All Phase 3

A Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of ALD-102 Solution in Subjects With Alopecia Areata

The goal of this first-in-human clinical trial is to learn if ALD-102 Solution is safe and well tolerated following injections in the scalp in subjects with alopecia areata. The study will also learn about the effect of ALD-102 on hair regrowth in treatment areas. The researchers will compare the effects …

18 - 55 years of age All Phase 1/2
B Bark-Lynn Lew

Safety and Efficacy of Oral NXC-736 in Adult Participants with Moderate and Severe Alopecia Areata

The purpose of this study is to evaluate the safety and efficacy of NXC-736 monotherapy in participants with severe alopecia areata (AA).

19 - 65 years of age All Phase 2
A Amy Paller, MD

Dupilumab in the Treatment of Pediatric Alopecia Areata

This is a prospective, randomized, double-blind, placebo-controlled clinical trial. The study will take place at four sites. This trial will enroll a total of 76 children and adolescents with moderate to severe AA (affecting at least 30% of the scalp) at the time of screening with a targeted 61 participants …

6 - 17 years of age All Phase 2

Simplify language using AI